PMA device
Hydrus Microsent
Alcon Research, LLC · Intraocular Pressure Lowering Implant (OGO, Class III) · First FDA decision Jun 4, 2021, newest Jun 4, 2021Glaucoma
Last checked: Nov 19, 2026Source: FDA, CMS, ClinicalTrials.gov, PubMed
FDA decisions
1
PMA pathway
Device trials
0
Naming "Hydrus Microsent"
MAUDE reports
0
Brand "Hydrus Microsent", since 2015
PubMed studies
0
Mentioning "Hydrus Microsent"
AI summary across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, MAUDE and PubMed data on this page, plus web searches for payment facts.
Product review deck
A slide deck reviewing Hydrus Microsent
About ten slides on the technology, clinical evidence, regulatory history and commercialization, built with AI from the data on this page and web research, with sources. Download it as PowerPoint to edit or as PDF to share.
- Executive summary and key facts
- Technology
- Clinical evidence and trials
- Regulatory history and safety
- Reimbursement, market and competition
- Risks, outlook and sources
AI-written from public data and may contain mistakes. Check each fact against its source before relying on it. Not investment, legal, reimbursement or medical advice.
FDA decisions
The newest 1 of 1 decisions filed under this name.
- Hydrus MicrosentPMA supplement
P170034-S005 · Decided Jun 4, 2021 · 179 days after receipt · Normal 180 Day Track No User Fee
Device type: Intraocular pressure lowering implant (OGO) · Ophthalmology
Medicare coverage
National and local coverage documents whose titles match this device or its device type. Payment add-ons (NTAP, pass-through, TCET) and likely codes are covered in the summary above.
- Implantable Pulmonary Artery Pressure Sensors for Heart Failure ManagementNational determinationOn the books20.36Updated Oct 6, 2026
- Implantable Pulmonary Artery Pressure Sensors for Heart Failure ManagementNational analysisReview closedCAG-00466NUpdated Sep 18, 2026
Clinical trials
Device studies on ClinicalTrials.gov that name "Hydrus Microsent", any status and sponsor, newest update first.
No registered device study names "Hydrus Microsent".
Adverse event reports (MAUDE)
Reports received since 2015 naming the brand "Hydrus Microsent", and for the whole product code for context.
This brand
0 reports: 0 malfunction, 0 injury, 0 death
Whole product code OGO
2,634 reports: 667 malfunction, 1,967 injury, 0 death
Newest reports for this brand
No MAUDE reports name this brand.
Recalls
From FDA's recall database. FDA lists each recalled product separately, so one recall can appear several times. A recall is often a correction or a labeling change, not a removal from the market.
No recall in FDA's data is linked to these FDA numbers.
Published research
The most relevant PubMed records for "Hydrus Microsent"[tiab]. The summary above synthesizes these.
No PubMed record mentions this device by name.
Other devices of this type
Also filed under product code OGO.
- iStent Trabecular Micro-Bypass Stent System, iStent inject Trabecular Micro-Bypass System, iStent inject W Trabecular MiGlaukos Corporation · PMA 2022
- iStent inject Trabecular MicroBypass SystemGlaukos Corporation · PMA 2025
- Hydrus MicrostentAlcon Research, LLC · PMA 2025
- iStent inject® W Trabecular Micro-Bypass System Model iS2Glaukos Corporation · PMA 2025
- CyPass System 241-SAlcon Research, Ltd. · PMA 2018
- Glaukos Trabecular Micro Bypass Stent Model GTS100R/LGlaukos Corporation · PMA 2013
- CyPass Micro-StentAlcon Research, Ltd. · PMA 2020
- iStent® Trabecular Mjcro-Bypass Stent System, Model GTS100Glaukos Corporation · PMA 2024
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.